-
Pediatrics Jan 1986
Topics: Child; Diuretics; Edema; Furosemide; Humans; Metolazone
PubMed: 3940353
DOI: No ID Found -
British Medical Journal (Clinical... Jun 1981
Topics: Aged; Diuretics; Drug Synergism; Furosemide; Humans; Metolazone; Middle Aged
PubMed: 6786661
DOI: 10.1136/bmj.282.6279.1873-a -
Child Nephrology and Urology 1990A combination of metolazone (0.2 mg/kg/day) and furosemide (4 mg/kg/day) was used in the treatment of a 2-week-old neonate who developed severe edema after cardiac...
A combination of metolazone (0.2 mg/kg/day) and furosemide (4 mg/kg/day) was used in the treatment of a 2-week-old neonate who developed severe edema after cardiac surgery. The edema, which was initially responsive to furosemide, became resistant to high doses of this diuretic even with the concomitant use of ethacrynic acid. The addition of metolazone to furosemide induced prompt diuresis and natriuresis. This combination of diuretics can be helpful in the treatment of refractory edema in young infants.
Topics: Drug Therapy, Combination; Edema; Female; Furosemide; Heart Defects, Congenital; Humans; Infant, Newborn; Metolazone; Postoperative Complications
PubMed: 2285924
DOI: No ID Found -
The Journal of Pharmacology and... Jan 1972
Clinical Trial
Topics: Adult; Bicarbonates; Calcium; Chlorides; Clinical Trials as Topic; Dehydration; Diuresis; Diuretics; Female; Humans; Hydrogen-Ion Concentration; Kidney; Kidney Function Tests; Kidney Glomerulus; Kidney Tubules; Magnesium; Male; Middle Aged; Quaternary Ammonium Compounds; Sodium; Spectrophotometry; Sulfonamides; Water-Electrolyte Balance
PubMed: 4551585
DOI: No ID Found -
Journal of the South Carolina Medical... Mar 1977
Topics: Adult; Aged; Diuretics; Female; Humans; Hypertension; Male; Metolazone; Middle Aged
PubMed: 266100
DOI: No ID Found -
British Medical Journal (Clinical... Dec 1981
Topics: Adult; Diuretics; Drug Synergism; Female; Furosemide; Humans; Metolazone
PubMed: 6796191
DOI: 10.1136/bmj.283.6306.1611-a -
Spectrochimica Acta. Part A, Molecular... Feb 2022In this study, a facile, rapid, and sensitive spectrofluorimetric method was evolved to analyse two antihypertensive drugs, namely, metolazone (MTZ) and valsartan (VST),...
In this study, a facile, rapid, and sensitive spectrofluorimetric method was evolved to analyse two antihypertensive drugs, namely, metolazone (MTZ) and valsartan (VST), in pharmaceutical and biological matrices. Both analytes exhibited intrinsic fluorescence activities which were significantly affected by environmental factors such as pH and solvent systems. However, simultaneous determination of MTZ and VST by conventional spectrofluorometry cannot be achieved simply because of the strong overlap between their fluorescence spectra. Thus, a combination of derivative and synchronous spectrofluorometry was conducted to overcome this dilemma. The proposed method relies on measurement of the first-order derivative of synchronous fluorescence intensity of the studied drugs at Δλ = 160 nm using 0.1 M acetic acid as the optimum solvent. The amplitudes of the first derivative synchronous fluorescence spectra of MTZ and VST were recorded at 236.0 nm (zero-crossing point of VST) and at 262.8 nm (zero-crossing point of MTZ) for simultaneous analysis of MTZ and VST, respectively. The fluorescent method was optimized efficiently to get the maximum selectivity and sensitivity by investigating different solvents, different buffer pHs, and different surfactants. The highest sensitivity and selectivity were achieved when 0.1 M acetic acid was used as a solvent. The method showed a linear concentration range of 10.0-100.0 ng mL and a limit of detection of <3.0 ng mL for each analyte. Statistical data analysis confirmed that no significant difference between the proposed spectrofluorometric method and the reference methods. The validity of the proposed spectrofluorometric method approved its suitability for quality control work. The proposed spectrofluorometric method was applied to assay the studied drugs in pharmaceutical dosage and in biological matrices with acceptable %recoveries and small RSD values.
Topics: Antihypertensive Agents; Metolazone; Pharmaceutical Preparations; Spectrometry, Fluorescence; Valsartan
PubMed: 34789407
DOI: 10.1016/j.saa.2021.120591 -
European Journal of Mass Spectrometry... Oct 2017Combination of metolazone (0.5 mg) and valsartan (80 mg) has been verified as a promising therapy treatment for hypertension. In order to facilitate to...
Combination of metolazone (0.5 mg) and valsartan (80 mg) has been verified as a promising therapy treatment for hypertension. In order to facilitate to pharmacokinetic research, it needs a method for the simultaneously determination of metolazone and valsartan in biological samples. However, there are no relative reports so far. In order to facilitate to pharmacokinetic research, an on-line solid phase extraction coupled with liquid chromatography-tandem mass spectrometry method for the simultaneous determination of metolazone and valsartan in beagle dog plasma was developed and validated in this study. An on-line solid phase extraction column Retain PEP Javelin (10 mm × 2.1 mm) was used to remove impurities in plasma samples. The metolazone, valsartan and internal standard (losartan) were separated on a Poroshell 120 SB-C18 column (4.6 mm × 50 mm × 2.7 µm) with a gradient elution procedure. Acidified acetonitrile/water mixture was used as a mobile phase. The selected multiple-reaction monitoring mode in positive ion was performed and the parent to the product transitions m/z 366/259, m/z 436.2/291 and m/z 423.4/207 were used to measure the metolazone, valsartan and losartan. The method was linear over the range of 0.1-100 ng/mL and 1-1000 ng/mL for metolazone and valsartan, respectively. This method was validated in terms of specificity, linearity, sensitivity, precision, accuracy, matrix effect, and stability and then successfully applied to pharmacokinetic studies of the metolazone and valsartan combination tablets in beagle dogs.
Topics: Animals; Chromatography, Liquid; Dogs; Linear Models; Male; Metolazone; Reproducibility of Results; Sensitivity and Specificity; Solid Phase Extraction; Tandem Mass Spectrometry; Valsartan
PubMed: 29028382
DOI: 10.1177/1469066717716726 -
BMJ Clinical Evidence May 2007Premenstrual symptoms occur in 95% of women of reproductive age. Severe, debilitating symptoms (PMS) occur in about 5% of those women. There is no consensus on how... (Review)
Review
INTRODUCTION
Premenstrual symptoms occur in 95% of women of reproductive age. Severe, debilitating symptoms (PMS) occur in about 5% of those women. There is no consensus on how symptom severity should be assessed, which has led to a wide variety of symptoms scales, making it difficult to synthesise data on treatment efficacy. The cyclical nature of the condition also makes it difficult to conduct RCTs.
METHODS AND OUTCOMES
We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of drug treatments; hormonal treatments; psychological interventions; physical therapies; dietary supplements; and surgical treatments in women with premenstrual syndrome? We searched: Medline, Embase, The Cochrane Library and other important databases up to November 2006 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
RESULTS
We found 52 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
CONCLUSIONS
In this systematic review we present information relating to the effectiveness and safety of the following interventions: acupuncture, alprazolam, bright light therapy, buspirone, chiropractic manipulation, clomipramine, cognitive behavioural therapy, danazol, endometrial ablation, evening primrose oil, exercise, gonadorelin analogues, hysterectomy, laparoscopic bilateral oophorectomy, magnesium supplements, metolazone, non-steroidal anti-inflammatory drugs, oestrogens, oral contraceptives, progesterone, progestogens, pyridoxine, reflexology, relaxation, selective serotonin reuptake inhibitors, spironolactone, tibolone.
Topics: Administration, Oral; Contraceptives, Oral; Dietary Carbohydrates; Dietary Supplements; Evidence-Based Medicine; Female; Humans; Life Style; Magnesium; Phytotherapy; Premenstrual Syndrome; Pyridoxine
PubMed: 19454075
DOI: No ID Found -
Medicina Clinica Jun 2024
PubMed: 38839442
DOI: 10.1016/j.medcli.2024.03.020